The Mitopure Challenge to Detect Levels of Urolithin A in Dried Blood Spots
Launched by AMAZENTIS SA · Jul 21, 2021
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The Mitopure Challenge is a clinical trial designed to study how well a specific test can measure levels of a substance called Urolithin A in dried blood samples collected at home. This trial is open to both men and women aged 18 to 80 who are generally healthy and willing to participate by taking the study product and completing some questionnaires. However, people who are pregnant, breastfeeding, or have certain medical conditions may not be eligible to join.
Participants can expect a virtual, home-based experience where they will collect their own blood samples and send them in for analysis. The main goal of the study is to see how reliable these home-collected samples are and to check how often samples might be rejected for testing. If you meet the eligibility criteria and are interested in helping advance research on healthy aging and diet, this trial could be a great opportunity for you!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Males and females 18 to 80 years of age;
- • 2. Is in general good health, as determined by the research team;
- • 3. Willingness to consume the investigation product, complete questionnaires and to complete the study;
- • 4. Have given voluntary, electronic, informed consent to be a participant in the study.
- Exclusion Criteria:
- • 1. Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial;
- • 2. Volunteers who plan to donate blood during the study or within 30 days of completing the study;
- • 3. Subject has a known allergy to the test material's active or inactive ingredients;
- • 4. Subjects with unstable medical conditions;
- • 5. Participation in a clinical research trial within 30 days prior to randomization;
- • 6. Allergy or sensitivity to study ingredients;
- • 7. Individuals who are cognitively impaired and/or who are unable to give informed consent;
- • 8. Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject;
- • 9. Has taken antibiotics within the previous 30 days.
About Amazentis Sa
Amazentis SA is a biotechnology company focused on advancing health through the development of innovative nutritional and therapeutic solutions. With a strong emphasis on scientific research and clinical validation, Amazentis leverages cutting-edge technologies to explore the potential of bioactive compounds in promoting metabolic health and enhancing overall well-being. The company is dedicated to transforming scientific discoveries into effective products that address pressing health challenges while maintaining a commitment to sustainability and evidence-based practices. Through strategic collaborations and rigorous clinical trials, Amazentis aims to contribute significantly to the fields of nutrition and health optimization.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Trial Officials
Anurag Singh, MD, PhD
Principal Investigator
Amazentis SA
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials